Clinical trials: Solid Tumor, completed
Cancer, Malignant Tumors
A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective…
- Trial name
- NCT00165802
- Testing
- E7974
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004220
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Study of Attention and Memory Treatments for Cancer Survivors
This clinical trial investigates if certain electronic games may be effective in improving attention and memory function in cancer survivors.
- Trial name
- NCT04870320
- Testing
- Endeavor: Computer-Based Cognitive Stimulation Intervention, Words!: Computer-Based Cognitive Stimulation Intervention, Quality of Life (QOL) Questionnaires
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Solid Tumor
A Study of of MORAb-004 in Subjects With Solid Tumors
The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.
- Trial name
- NCT00847054
- Testing
- MORAb-004 (monoclonal antibody to TEM1)
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Morphotek
Solid Tumours
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation…
- Trial name
- NCT01928940
- Testing
- dabrafenib, trametinib
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited
Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
Liposomal formulations are frequently used today in the treatment of cancer. LiPlaCis is the first targeted liposomal formulation with a tumour triggered release mechanism to undergo clinical development in oncology and it is…
- Trial name
- LiPlaCis (NCT01861496)
- Testing
- LiPlaCis
- Where
- 4 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Allarity Therapeutics
Advanced Solid Tumors
Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics, and pharmacodynamics of U3-1287 (AMG 888), a fully human monoclonal antibody targeting the HER3 receptor, in patients with advanced solid tumors.
- Trial name
- NCT00730470
- Testing
- U3-1287 (AMG888)
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- U3 Pharma GmbH
Cachexia, Malignant Solid Neoplasm
Ultrasound in Evaluating Muscle-Glycogen Content in Cancer Patients
This trial studies how well an ultrasound procedure (non-invasive MuscleSound technology) can be used to learn about levels of glycogen (a type of sugar) in cancer patients during inpatient rehabilitation.
- Trial name
- NCT03982082
- Testing
- Physical Therapy, Questionnaire Administration, Ultrasound
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
This is a phase 1 study of TAS-114 in combination with S-1 in patients with advanced solid tumors.
- Trial name
- NCT01610479
- Testing
- TAS-114 + S-1
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Bladder Cancer, Urothelial Carcinoma
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
- Trial name
- NCT03980041
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 29 sites in United States, Czechia and 5 more
- Volunteers
- 49 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Neoplasms
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Study to determine the maximum tolerated dose of BIBW 2992 when combined with backbone chemotherapies consisting in cisplatin plus paclitaxel or cisplatin plus 5 FU.
- Trial name
- NCT00716417
- Testing
- BIBW 2992
- Where
- 3 sites in Belgium
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Neoplasms
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
- Trial name
- NCT00207090
- Testing
- ixabepilone, Rifampin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- R-Pharm
Unspecified Adult Solid Tumor, Protocol Specific
Individual Counseling and/or Computer-Based Counseling in Helping Healthy Women Adopt a Cancer Prevention Diet
RATIONALE: Eating a diet high in fruits and vegetables and low in fat may lower the risk of some types of cancer. Dietary counseling may be effective in helping women change to a healthy diet.
- Trial name
- NCT00217490
- Testing
- dietary counseling via computer, dietary counseling via nutritionist, combined computer and nutritionist
- Where
- 3 sites in United States
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Adult Solid Neoplasm
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
This phase I trial studies the side effects and best dose of sunitinib malate when given together with hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy.
- Trial name
- NCT00813423
- Testing
- Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
The purpose of this study is to determine whether corrected QT (QTc) interval changes occur on an electrocardiogram (ECG) when cetuximab is administered to the study population.
- Trial name
- NCT00698841
- Testing
- Cetuximab
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Eli Lilly and Company
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003109
- Testing
- irinotecan hydrochloride, raltitrexed
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Fox Chase Cancer Center
Solid Tumors
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation…
- Trial name
- NCT01445509
- Testing
- Bevacizumab, Dasatinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Solid Tumors
A Phase I Study of TAS-102 in Solid Tumors
The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.
- Trial name
- NCT02261532
- Testing
- TAS-102
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.